Icosavax’s virus-like particle (VLP) technology, developed at UW’s Institute for Protein Design (IPD), is designed to address a challenge that has impeded wider use of VLP vaccines: How to construct and manufacture VLPs capable of displaying complex viral antigens that have been difficult to successfully produce at scale, including for RSV and hMPV . . .

Get GEN Edge Today!

The post Icosavax: Giving VLPs the VIP Treatment appeared first on GEN – Genetic Engineering and Biotechnology News.

Source